Detection of molecular targets on the surface of CD34⁺CD38⁻ bone marrow cells in myelodysplastic syndromes

Abstract

Myelodysplastic syndrome (MDS) is a kind of clonal stem-cell disorder in which aberration within a hematopoietic stem cell (HSC) gives rise to the entire disease as in acute myeloid leukemia (AML). Studies have showed that contrasting normal stem cells, AML stem cells express CD96 and CD123, but lack of CD90, although both of them reside within the CD34 1 CD38 2 population. So far, little is known about expression of the markers on MDS HSC. In this study, we analyzed the immunophenotypic characteristics of CD34 1 CD38 2 bone marrow (BM) cells by multicolor flow cytometry in 38 patients with MDS and 10 control patients. We found that CD34 1 CD38 2 BM cells coexpressed CD13, CD33, CD117, CD133, and HLA-DR almost in all patients, but in MDS they expressed higher amounts of CD13 (79% AE 16% vs. 36% AE 13%, P < 0.05) and CD133 (66% AE 20% vs. 25% AE 13%, P < 0.05). CD90 was expressed in all control patients but just in 63% of patients with MDS. No control patients had an expression of CD2, CD5, CD7, CD44, CD96, and CD123, which expressed variable amounts in 17-53% of patients with MDS. The level of CD13 in RCMD (89% AE 7%), RAEB-1 (88% AE 11%), and RAEB-2 (81% AE 13%) were obviously higher than that of RA (63% AE 16%, P < 0.05). CD2, CD5, and CD7 were more frequently observed in RAEB or INT and HIGH-R cases. Taken together, we demonstrate MDS stem cells display deranged phenotypic abnormalities that may make them particularly difficult to eradicate using therapies targeted against surface antigens, and the percentage of cells expressing CD13 is notably higher in patients with high-grade MDS that may be a potential prognostic indicator of MDS in the future. ' 2010 International Society for Advancement of Cytometry

CD34+/CD38− acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells

“…Additional differentially expressed proteins are also listed in Supporting Information Table S1. Other studies identified aldehyde dehydrogenase activity (ALDH), B‐cell lymphoma/leukemia 11A (BCL11A), ILK, and HLA‐DR as highly expressed proteins in leukemia stem cells 28–31. These proteins were also overexpressed in CD34 + /CD38 − AML cells in the present study (Table 2), indicating an acceptable sensitivity of the current study.…”

Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker

“…In haematological malignancies, identification of cells with different growth capacities is based on cell surface antigens and these exhibit functional heterogeneity [42]. Flow cytometry is a widespread and reliable method to detect antigens on single cells [43]. We analyzed cell surface antigens on single cell suspensions derived from xenografted tumours from our colon carcinoma cell line panel.…”

In search for cross‐reactivity to immunophenotype equine mesenchymal stromal cells by multicolor flow cytometry

“…In stem cell research in general and MSC research in specific, immunophenotyping is preferably performed by multicolor flow cytometry to simultaneously demonstrate the coexpression of specific MSC markers and the absence of hematopoietic antigen expression (7,14). However, many flow cytometric techniques have been developed for analyzing mature, nonadherent leukocytes, and therefore, some refinements are required when using stem cells (15).…”